Australian Patent Amendments To Trade Pact Face Scrutiny From PhRMA, USTR
This article was originally published in The Pink Sheet Daily
Last-minute changes to the Australian law implementing the free trade deal may violate the underlying agreement and WTO rules on patent rights, PhRMA says. The amendments are designed to block “evergreening” practices by brand name drug makers.
You may also be interested in...
The U.S. pharmaceutical industry has its first formal mechanism to challenge foreign price controls following the signing of the U.S.-Australia free trade agreement by President Bush Aug. 3
The reimportation issue is still being debated in Congress, Grassley notes. The trade agreement calls for changes to Australia's Pharmaceutical Benefits Scheme, including independent review of product inclusion.
FDA asks Endo to disseminate “corrective messages” to doctors who received the violative promotional materials, which the agency says omit risk information and contain unsubstantiated effectiveness claims.